## Contents

### Chapter 1 Hemostasis Physiology

**Coagulation Pathway and Physiology**

Russell A. Higgins, MD

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
</tr>
</tbody>
</table>

**Introduction**, 3

**Constituents of the Hemostatic System**, 3

**Endothelium**, 3

- Prothrombotic Properties of Endothelium, 4
- Antithrombotic Properties of Endothelium, 5
- Coordinating Prothrombotic and Antithrombotic Properties of Endothelium, 6

**Platelets**, 6

**Coagulation Proteins**, 7

**The Extrinsic Pathway and the Prothrombin Time**, 9

**The Intrinsic Pathway and the Activated Partial Thromboplastin Time**, 9

**The Prothrombin Time and Activated Partial Thromboplastin Time Pathways**, 9

**Newer Coagulation Model**, 10

- **Initiation**, 11
- **Amplification**, 12
- **Propagation**, 12

**Regulatory Mechanisms**, 13

- **Protein C and Protein S System**, 14
- **Protease Inhibitors**, 14

**Operation of the Hemostasis and Thrombosis Pathway**, 15

**Suggested Reading**, 15

### Chapter 2 Platelet Structure and Function

Imran Mirza, MD, and Kandice Kottke-Marchant, MD, PhD

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
</tr>
</tbody>
</table>

**Platelet Production**, 17

**Megakaryocyte Development and Maturation**, 17

**Platelet Production from Megakaryocytes**, 19

**Platelet Structure**, 19

- **Surface Glycoproteins and Plasma Membrane**, 19
- **Von Willebrand Receptor (GPIb/IX/V)**, 19
- **Collagen Receptors (GPVI and GPIa/IIa)**, 20
- **Adenosine Diphosphate Receptors**, 21
- **Alpha-2 Adrenergic Receptors for Epinephrine**, 21
- **Thrombin Receptors (PAR-1 and PAR-4)**, 21
- **Thromboxane Receptor and Prostaglandin Receptors**, 22
- **Fibrinogen Receptor (GPIIb/IIIa)**, 22
- **CD36 (GPIV)**, 23
- **CD31 (Platelet Endothelial Cell Adhesion Molecule-1)**, 23
- **Platelet Cytoskeleton**, 24
- **Platelet Membrane Systems**, 25
- **Platelet Granules**, 25
  - **Alpha Granules**, 25
  - **Dense Granules**, 26
Platelet Activation, 26
Platelet Adhesion, 27
   Role of GPIb/IX/V and von Willebrand Factor, 27
   Role of Collagen Receptors, 28
Cytoskeletal Changes, 29
Platelet Activation and Granule Release, 29
   Phospholipase Pathway, 29
   Cyclooxygenase Pathway, 29
   Platelet Granule Release, 29
Platelet Aggregation, 30
Platelet Procoagulant Activity, 31
Immune and Inflammatory Roles of Platelets, 31
Suggested Reading, 31

Chapter 3  Fibrinolytic System Physiology  
Marc D. Smith, MD, and Wayne L. Chandler, MD
History, 33
Proteins and Function, 33
Regulation of Fibrinolysis, 37
Fibrinolysis at the Site of a Thrombus, 39
Suggested Reading, 39

Basics of Laboratory Testing in Hemostasis

Chapter 4  Specimen Collection and Processing  
Jayashree Krishnan, MD, and Dorothy M. Adcock, MD
Introduction, 43
Specimen Collection Technique for Peripheral Venipuncture, 43
   Needle Selection for Venipuncture, 44
   Tourniquet Effect, 44
   Use of Winged Collection Sets, 44
   Specimen Labeling, 44
Blood Collection From Indwelling Lines and Catheters, 45
Blood Collection Tubes and Anticoagulant Considerations, 45
   Blood Collection Tubes, 45
   Blood Tube Draw Order, 45
   Anticoagulant, 46
   Volume Effect, 46
   Hematocrit Effect, 47
Transportation of Whole Blood Specimens to the Laboratory, 47
Sample Processing, 47
   Preparation of Platelet-Poor Plasma, 48
   Effects of Temperature and Time, 48
   Causes for Specimen Rejection, 51
   Specimen Collection and Storage for Molecular Coagulation Assays, 52
Conclusion, 53
Suggested Reading, 53
Case Study, 51

Chapter 5  Clinical History in Hemostasis and Thrombosis  
Vandita Johari, MD
Introduction, 55
Clinical History in Bleeding Patients, 55
   Bleeding Scores (Bleeding Assessment Tool), 55
   Determine Whether the Patient Has Excessive Bleeding, 57
      Extent of Bleeding, 57
      Duration of Bleeding Abnormality, 58
      Type of Bleeding, 59
Fibrinogen Assay, 83
  Clinical Utility of Fibrinogen Assays, 85
Assay of Specific Factors, 85
  Principle, 85
  Factor II (Prothrombin), 86
  Factors V, VII, and X, 86
  Factors VIII, IX, XI, XII, High-Molecular-Weight Kininogen,
  and Prekallikrein, 86
  False-Positives and False-Negatives in Factor Assays, 87
  Factor XIII, 87
  Von Willebrand Factor, 87
Mixing Studies, 88
  Principle, 88
  Technical Considerations, 88
  Procedure, 90
  Criteria for Interpretation of Mixing Studies, 90
Specific Inhibitor Studies, 90
  Bethesda Assay, 90
  Nijmegen Modification, 91
  Reporting of Results, 91
Establishing Reference Ranges and Validating Coagulation Laboratory Testing, 92
  Preanalytic and Postanalytic Considerations, 92
  Reference Range, 92
  Accuracy, 92
  Precision, 93
  Linearity, 93
  Interfering Conditions, 93
  Issue of Duplicate Testing, 95
  Turnaround Time, 95
  Reporting of Results, 96
Summary, 96
Suggested Reading, 97
Case Study, 95

Chapter 7 Platelet Testing
Megan O. Nakashima, MD, and Kandice Kottke-Marchant, MD, PhD
Patient History, 99
  Clinical History for Patients With a Bleeding Diathesis, 99
  Clinical History for Patients With Thrombosis, 99
Platelet Count, Indices, and Morphology, 100
  Specimen Collection and Processing Considerations, 100
  Test Performance and Interpretation, 101
Bone Marrow Analysis, 102
  Specimen Collection and Processing Considerations, 102
  Bone Marrow Interpretation, 103
Platelet Function Testing, 103
  Bleeding Time, 103
  PFA-100, 104
    Specimen Considerations, 104
    Test Performance and Interpretation, 104
  Platelet Aggregation, 106
    Light Transmission Aggregation, 107
      Specimen Considerations, 107
      Test Performance and Interpretation, 107
    Whole Blood Aggregometry, 109
    Plateletworks, 110
    VerifyNow, 110
Release Assays, 111
  Lumiaggregation, 111
  Release Markers, 111
  P-selectin, 111
  Thromboxane Metabolites, 112
Adhesion Assays, 112
  Platelet Adhesion Chambers, 112
  Impact Cone and Plate(let) Analyzer, 112
Platelet Mechanical Assays, 113
  Hemostasis Analysis System, 113
  Whole Blood Viscoelastometry, 113
Flow Cytometry, 114
  Platelet Turnover (Platelet Reticulocyte Analysis), 115
Electron Microscopy, 116
Platelet Genetic Testing, 117
Summary, 118
Suggested Reading, 118

Chapter 8  Fibrinolysis Testing
Wayne L. Chandler, MD
Clinical History Suggesting the Need for Fibrinolytic Testing, 121
Sample Collection and Processing for Fibrinolytic Testing, 121
D-Dimer and Fibrin Split Product Assays, 123
Plasminogen Assays, 125
Alpha-2 Antiplasmin Assays, 126
Tissue Plasminogen Activator Assays, 126
Plasminogen Activator Inhibitor-I Assays, 128
Global Tests of Fibrinolysis, 129
Lipoprotein (a), 130
Genomic Assays, 131
Research Assays, 131
Suggested Reading, 131

Chapter 9  Laboratory Aspects of Thrombophilia Testing
Charles Eby, MD
Introduction, 133
Inherited Thrombophilias: Natural Anticoagulants, 133
  Protein C, 133
    Protein C Functional Assays, 133
    Protein C Antigen Assays, 135
  Protein S, 136
    Protein S Activity Assays, 137
    Protein S Antigen Assays, 137
  Antithrombin, 138
    Antithrombin Functional Assays, 138
    Antithrombin Antigen Assays, 139
  Activated Protein C Resistance, 139
    Activated Protein C Resistance Assays, 139
  Factor VIII Activity, 140
Fibrinogen Abnormalities, 140
  Lupus Anticoagulant, 141
Factor V Leiden and Prothrombin G20210A Mutations, 141
Plasma Homocysteine Concentration, 142
Global Tests of Hypercoagulability, 143
  Endogenous Thrombin Potential, 143
    Undiluted Activated Protein C Resistance, 143
    Activated Partial Thromboplastin Time, 143
    Activation and Degradation Peptides, 144
Chapter 10 Quality in Hemostasis Laboratory Testing

Paul Allison, MD, and Kandice Kottke-Marchant, MD, PhD

History of Hemostasis Laboratory Quality Initiatives, 147
Quality Management Programs, 147
Purpose of a Quality Plan, 147
Implementing a Hemostasis Quality Plan, 148
Quality Management for Coagulation Screening Tests, 149
Standard Operating Procedures, 150
Quality Control, 151
Frequency of Quality Control Testing, 153
Quality Assurance, 153
Evidence of Compliance, 153
External Quality Assessment, 154
Laboratory Quality Data in Patient Care, 156
Summary, 157
Suggested Reading, 157

Chapter 11 Abnormal Activated Partial Thromboplastin Time

Russell A. Higgins, MD, and John D. Olson, MD, PhD

Introduction, 161
Clinical Etiologies, 161
Coagulation Factor Deficiency Associated With Significant Hemorrhage, 161
Von Willebrand Disease, 161
Factor VIII Deficiency, 162
Factor IX Deficiency, 163
Factor XI Deficiency, 163
Other Inherited and Acquired Deficiencies, 163
Coagulation Factor Deficiencies Not Associated With Bleeding, 163
Prolongation of aPTT Due to Inhibitors, 164
Medications, 164
Lupus Anticoagulant, 164
Specific Coagulation Factor Inhibitors, 165
Alloantibodies in Hemophilic Patients, 165
Autoantibodies to Factor VIII and Other Factors, 166
Spurious Causes of an Elevated aPTT, 166
Laboratory Testing Algorithm, 167
Accelerated aPTT, 170
Spurious, 170
Treatment With Activated Clotting Factors, 170
Consumptive Coagulopathy, 170
Summary, 170
Suggested Reading, 171
Case Studies, 170, 171

Chapter 12 Prolonged Prothrombin Time

Mark T. Cunningham, MD, and Marc D. Smith, MD

Introduction, 173
Differential Diagnosis of a Corrected Mixing Study, 173
Hereditary Disorders: Factor Deficiency, 174
Factor II Deficiency, 174
Factor V Deficiency, 175
Factor V and Factor VIII Deficiency, Combined, 175
Factor VII Deficiency, 176
Factor X Deficiency, 176
Chapter 13 Abnormal Thrombin Time 187
Mark T. Cunningham, MD, and Sandra C. Hollensead, MD

Introduction, 187
Clinical Indications, 187
Differential Diagnosis, 187

Amyloidosis, 187
Autoantibodies, 187
Drugs, 188

Bovine Thrombin, Topical, 188
Direct Thrombin Inhibitors, 189
Heparin, 189
Plasminogen Activators, 189
Volume Expanders, 189
Fibrin Degradation Products, 190
Fibrinogen Abnormalities, 190

Dysfibrinogenemia, 190
Hypofibrinogenemia, 190
A fibrinogenemia, 193
Hyperfibrinogenemia, 193
Radiocontrast Agents, 193
Algorithm, 193
Suggested Reading, 193
Case Studies, 190, 191

Chapter 14 Normal Prothrombin Time and Activated Partial Thromboplastin Time 195
Vandita Johari, MD

Introduction, 195
Clinical Evaluation, 195
False-Negative (Normal) PT and aPTT, 196
Patient-Specific Causes, 196
Preanalytic Causes, 196
Analytic Causes, 196
An Algorithmic Approach to Hemostasis Testing

Postanalytic Causes, 196
Additional Testing, 196
  Primary Hemostasis Defects, 196
  Secondary Hemostasis Defects, 197
    Factor Assays, 197
    Factor XIII Deficiency, 197
  Fibrinolysis Defects, 199
  Vascular Disorders, 199
Algorithm, 199
Suggested Reading, 200
Case Studies, 199, 200

Chapter 15  Fibrinolytic Bleeding Disorders 201
Wayne L. Chandler, MD

Introduction, 201
Clinical Evaluation of Fibrinolytic Bleeding Disorders, 201
Plasminogen Activator Inhibitor-1 Deficiency, 201
Alpha 2-Antiplasmin Deficiency, 203
Quebec Platelet Disorder, 203
Factor XIII Deficiency, 203
Acquired Causes of Fibrinolytic Bleeding, 203
  Mechanisms of Acquired Fibrinolytic Bleeding, 203
  Cardiovascular Surgery and Cardiopulmonary Bypass, 204
  Cirrhosis and Liver Transplantation, 205
Monitoring Fibrinolysis, 205
Menorrhagia, 205
Trauma, 206
Disseminated Intravascular Coagulation, 206
Suggested Reading, 210
Case Studies, 205, 206

Chapter 16  Platelet Disorders 211
Kandice Kottke-Marchant, MD, PhD

Introduction, 211
Platelet Dysfunction With Normal Platelet Count (Qualitative Platelet Disorders), 211
  Glycoprotein Disorders, 213
    Glanzmann Thrombasthenia (GPIIb/IIIa Deficiency), 213
    GPIb/IX/V (Bernard-Soulier Syndrome), 218
    Platelet-Type von Willebrand Disease, 218
  Collagen Receptor Disorders (GPIa/IIa and GPVI), 218
  Adenosine Disphosphate Receptor Abnormalities, 219
Platelet Release Defects, 219
  Storage Pool Disorders (Alpha and Dense Granule Disorders), 219
  Signal Transduction Disorders, 221
  Disorders of Platelet Procoagulant Activity (Scott Syndrome), 222
Platelet Disorders With Thrombocytosis, 222
  Reactive Thrombocytosis, 222
  Myeloproliferative Neoplasms Associated With Thrombocytosis, 223
Platelet Disorders With Thrombocytopenia, 224
  Thrombocytopenia With Increased Platelet Size
    (Macrothrombocytopenia Disorders), 224
    Macrothrombocytopenias With Neutrophilic Inclusions
    (MYH9-Related Diseases), 224
    Bernard-Soulier Syndrome, 227
    Gray Platelet Syndrome (Alpha Granule Storage Pool Disorder), 228
  Thrombocytopenia With Decreased Platelet Size, 229
    Wiskott-Aldrich Syndrome and X-Linked Thrombocytopenia, 229
    Thrombocytopenia With Normal Platelet Size, 229
Peripheral Platelet Destruction, 230
   Immune Destructive Thrombocytopenias, 230
   Nonimmune Destructive Thrombocytopenias, 232
Decreased Platelet Production, 233
   Inherited Thrombocytopenias With Decreased Platelet Production, 233
   Defects of Platelet Production, 233
   Acquired Thrombocytopenias With Decreased Platelet Production, 234
   Platelet Dysfunction Associated With Other Illnesses, 234
Platelet Disorders Associated With Thrombosis or Platelet Activation, 234
   Platelet Activation, 235
   Genetic Polymorphisms Associated With Thrombosis and Cardiovascular Disease, 235
   Cardiovascular Devices, 236
Summary, 236
Suggested Reading, 237
Case Study, 211

Chapter 17  Von Willebrand Disease  241
Elizabeth M. Van Cott, MD, and Arnaud Drouin, MD
Introduction, 241
Von Willebrand Factor, 241
Clinical Features, 241
   Classification, 242
   Inheritance, 244
Laboratory Testing, 244
   Laboratory Findings in Type 1 von Willebrand Disease, 248
   Laboratory Findings in Type 2 von Willebrand Disease, 248
   Laboratory Findings in Type 3 von Willebrand Disease, 249
The Molecular Basis of von Willebrand Disease, 249
Acquired von Willebrand Disease, 250
Treatment, 250
Suggested Reading, 251
Case Study, 244

Chapter 18  Emergency Assessment of Hemostasis in the Bleeding Patient  253
Wayne L. Chandler, MD
Clinical Situation, 253
Clinical Criteria for Emergency Hemostasis Testing, 253
Options for Testing Locations, 253
Testing Methodology for Emergency Hemostasis Evaluation, 254
   Standard Assays, 254
   Point-of-Care Analyzers, 256
   Viscoelastic Global Hemostasis Assays, 256
   Platelet Function Assays, 257
Summary, 258
Suggested Reading, 258

4  Algorithmic Approach to Thrombophilic Disorders

Chapter 19  Arterial and Venous Thrombosis in Adults  261
Russell A. Higgins, MD, and John D. Olson, MD, PhD
Introduction, 261
General Considerations, 261
   Consent and Counseling, 261
   Assay Calibration, Reference Range, and Assay Reliability, 261
   Combined Deficiency, 262
Testing for Thrombophilic Risk in Patients With Venous or Arterial Thrombosis, 262
   Thrombophilic Risk Factor Testing in Venous Thromboembolism, 262
   How Does Thrombophilia Testing Impact Medical Decisions?, 262
An Algorithmic Approach to Hemostasis Testing

Who Should Be Tested for Thrombophilic Risk?, 263
What Tests Should Be Performed?, 268
When Should Thrombophilia Testing Be Performed?, 268
Recommendations for Testing of Individual Analytes, 269
Protein C, Protein S, and Antithrombin Deficiency, 269
Factor V Leiden and Prothrombin G20210A Mutations, 270
Hyperhomocysteinemia and High Concentrations of Factor VIII, 271
Acquired Thrombophilic Risk Factors, 271
Antiphospholipid Antibodies, 271
Heparin-Induced Thrombocytopenia, 271
Thrombophilic Risk Factor Test Selection in Arterial Thrombosis, 272
Antiphospholipid Antibodies, 272
C-Reactive Protein, 273
Lipoprotein (a), 273
Homocysteine, 273
Prothrombin G20210A Mutation, 274
Factor V Leiden (Activated Protein C Resistance), 274
Deficiencies of Protein C, Protein S, and Antithrombin, 275
Coagulation Factors, 275
Heparin-Induced Thrombocytopenia, 275
Thrombophilic Risk Factor Test Selection in Neurovascular Thrombosis, 276
Antiphospholipid Antibodies, 276
Lipoprotein (a), 276
Homocysteine, 276
Prothrombin G20210A Mutation, 277
Factor V Leiden (Activated Protein C Resistance), 277
Deficiencies of Protein C, Protein S, and Antithrombin, 277
Heparin-Induced Thrombocytopenia, 278
Additional Considerations for Thrombosis in Unusual Sites, 278
Myeloproliferative Neoplasms and JAK2V617F, 279
Paroxysmal Nocturnal Hemoglobinuria, 279
Warfarin-Induced Skin Necrosis, 280
Suggested Reading, 280
Case Studies, 263, 264

Chapter 20  Unique Issues of Thrombophilia in Women and Children  285
S. Kate Hartman, MD, and John D. Olson, MD, PhD
Introduction, 285
Pregnancy and Hormonal Therapy, 285
Baseline Thrombotic Risk in Women, 285
Oral Contraceptives and Risk of Thromboembolism, 288
Hormone Replacement Therapy and Venous Thromboembolism, 291
Thrombophilia in the Pediatric Setting, 292
Description of the Problem, 292
Testing for Thrombophilia in Children, 294
Suggested Reading, 296
Case Studies, 291, 292

Chapter 21  Laboratory Diagnosis of Inherited Thrombophilia  299
Charles Eby, MD
Introduction, 299
Algorithmic Approach to Laboratory Diagnosis of Thrombophilic Risk Factors, 299
Protein C, 300
Protein S, 302
Antithrombin, 303
Factor VIII, 305
Activated Protein C Resistance and Factor V Leiden, 305
Chapter 25  Thrombotic Microangiopathies
Dorothy M. Adcock, MD, Karen A. Moser, MD, and Dong Chen, MD, PhD

Introduction, 337
Definition and Clinical Features of Thrombotic Microangiopathies, 337
Thrombotic Thrombocytopenic Purpura, 338
Biology of von Willebrand Factor and ADAMTS13, 338
A Brief History of Thrombotic Thrombocytopenic Purpura, 340
Clinical Presentation of Thrombotic Thrombocytopenic Purpura, 341
Laboratory Testing in Thrombotic Thrombocytopenic Purpura, 342

ADAMTS13 Testing, 342
ADAMTS13 Activity Assays, 342
ADAMTS13 Activity Assay Interferences, 346
Interpretation of ADAMTS13 Activity Results, 346
ADAMTS13 Antigen Assays, 347
Anti-ADAMTS13 Autoantibody Assessment, 347
Mutation Analysis of ADAMTS13, 347
Thrombotic Thrombocytopenic Purpura Treatment, 347
Prediction of Severity and Mortality of Acute Thrombotic Thrombocytopenic Purpura, 348
Prediction of Thrombotic Thrombocytopenic Purpura Relapse, 348
Thrombotic Microangiopathies Other Than TTP, 349
Shiga Toxin–Associated Hemolytic Uremic Syndrome, 349
Atypical Hemolytic Uremic Syndrome, 350
Pregnancy-Related Thrombotic Microangiopathies, 351
Hematopoietic Stem Cell Transplant–Associated Thrombotic Microangiopathy, 351
Malignancy-Associated Thrombotic Microangiopathy, 352
Other Considerations, 352
Suggested Reading, 352
Case Study, 338

Chapter 26  The Value of Consultation in Hemostasis Testing
Kandice Kottke-Marchant, MD, PhD, and Marc D. Smith, MD

Introduction, 357
The Drive for Added Value in Laboratory Testing, 357
Institutions Influencing Change in Health Care Delivery, 357
The New Laboratory Value Focus, 358
Unique Features of Hemostasis Testing That Make Consultation Valuable, 359
Basic Elements and Benefits of an Interpretive Hemostasis Service, 360
Operational Process for an Interpretive Hemostasis Service, 361
Model Algorithm for an Elevated aPTT Panel, 363
Model Algorithm for a Hypercoagulation Panel, 365
Elements of the Interpretive Report, 366
Impact of an Interpretive Hemostasis Service, 367
Quality Assessment in Interpretive Reporting, 367
Summary and Conclusion, 368
Suggested Reading, 368
Case Study, 366

5  Antiplatelet and Anticoagulant Drugs

Chapter 27  Overview of Antithrombotic Agents
Karen A. Moser, MD

Introduction, 373
Target Therapeutic Range and Monitoring Considerations, 373
Common Clinical Settings Where Antithrombotic Agents Are Used, 374
Acute Venous Thromboembolism, 374
Prophylaxis for Venous Thromboembolism, 375
Chapter 28  Mechanism and Monitoring of Anticoagulant Agents  379
Dorothy M. Adcock, MD, and Karen A. Moser, MD
Introduction, 379
Unfractionated Heparin, 379
  Laboratory Detection and Monitoring of Unfractionated Heparin, 380
    Acute Venous Thromboembolism, 384
    Acute Coronary Syndromes, 384
    Renal Dialysis, Percutaneous Coronary Intervention, and Cardiopulmonary Bypass, 385
Low-Molecular-Weight Heparins, 385
  Laboratory Detection and Monitoring of Low-Molecular-Weight Heparins, 385
Fondaparinux, 386
  Laboratory Detection and Monitoring of Fondaparinux, 387
Direct Thrombin Inhibitors, 387
  Hirudins (Peptide Direct Thrombin Inhibitors), 387
  Laboratory Detection and Monitoring of Hirudin Analogues, 388
Argatroban, 389
  Laboratory Detection and Monitoring of Argatroban, 389
Dabigatran, 390
  Laboratory Detection of Dabigatran, 391
Vitamin K Antagonists, 392
  Laboratory Detection and Monitoring of Vitamin K Antagonists, 393
Direct Anti-Xa Inhibitors, 394
  Rivaroxaban, Apixaban, and Edoxaban, 394
    Laboratory Detection of Rivaroxaban and Apixaban, 396
Interference of Direct Thrombin Inhibitor and Direct Anti-Xa Inhibitor Anticoagulants in Special Coagulation Assays, 397
  Direct Thrombin Inhibitors, 397
  Direct Xa Inhibitors, 397
Suggested Reading, 399

Chapter 29  Antiplatelet Agents  403
Kandice Kottke-Marchant, MD, PhD
Introduction, 403
Parenteral Agents, 403
  Glycoprotein IIb/IIIa Inhibitors, 403
    Mechanism of Action, 403
    Effect on Platelet Function Tests, 406
    Clinical Uses, 406
    Role of Monitoring, 407
    Special Issues, 407
Oral Agents, 407
  Aspirin, 407
    Mechanism of Action, 407
    Clinical Uses, 408
    Laboratory Tests Used to Assess Effect, 408
    Laboratory Monitoring, 409
P2Y₁₂ Inhibitors, 410
Chapter 30  **Antifibrinolytic and Thrombolytic Agents**
Wayne L. Chandler, MD

Introduction, 425
Therapeutic Uses of Antifibrinolytic Drugs, 427
   - Cardiovascular Surgery and Cardiopulmonary Bypass, 427
   - Liver Transplantation, 427
   - Trauma, 428
   - Orthopedic and Spinal Surgery, 428
   - Genitourinary Bleeding, 428
   - Gastrointestinal Bleeding, 428
   - Other Indications, 429
   - Monitoring of Antifibrinolytic Drugs, 429
Thrombolytic Agents, 429
   - Monitoring of Thrombolytic Agents, 432
Suggested Reading, 432
*Case Studies, 431*

**Appendices and Index**

Appendix A. Acronyms List, 437
Appendix B. Example Reference Ranges, 440
Index, 441